Dupilumab
- PDF / 168,758 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 94 Downloads / 177 Views
1 S
Facial redness and ocular surface disease: case report In a single-institution retrospective study, a patient [age and sex not stated] was described, who developed dupilumab facial redness (DFR) and dupilumab ocular surface disease (DOSD) during treatment with dupilumab for atopic dermatitis [dosage, route, duration of treatment to reactions onsets and outcomes not stated]. Muzumdar S, et al. Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review. Journal of the American Academy of 803519057 Dermatology 83: 1520-1521, No. 5, Nov 2020. Available from: URL: http://doi.org/10.1016/j.jaad.2020.06.1003
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
